Release Date: 30-Aug-2023
Kimmtrak, developed by Immunocore, was approved to treat uveal melanoma in early 2022. It is the first bispecific antibody to be approved for the treatment of a solid tumor, as well as the first bispecific T cell engager to receive approval. Kimmtrak has reportedly become the most recommended drug for HLA*02:01 positive patients with metastatic uveal melanoma, which has fueled its quarterly and annual sales growth. The global sales reported for Kimmtrak’s were GBP 116.8 million (US$ 147.168 million) for the year 2022, and GBP 87.6 million (US$ 110.38 million) in the first half of 2023. The US is the major market for Kimmtrak, because of the large number of cancer patients in the region, followed by France and Germany. Sales of Kimmtrak are projected to skyrocket in the coming years as it continues to receive regulatory approval in other regional markets.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028